Valeo Financial Advisors LLC raised its holdings in ABIOMED, Inc. (NASDAQ:ABMD) by 33.8% during the first quarter, Holdings Channel reports. The fund owned 499 shares of the medical equipment provider’s stock after purchasing an additional 126 shares during the period. Valeo Financial Advisors LLC’s holdings in ABIOMED were worth $143,000 at the end of the most recent reporting period.

A number of other institutional investors have also added to or reduced their stakes in the business. Vanguard Group Inc. grew its position in ABIOMED by 5.9% in the third quarter. Vanguard Group Inc. now owns 4,647,227 shares of the medical equipment provider’s stock valued at $2,090,091,000 after acquiring an additional 260,829 shares during the last quarter. Vanguard Group Inc grew its position in ABIOMED by 5.9% in the third quarter. Vanguard Group Inc now owns 4,647,227 shares of the medical equipment provider’s stock valued at $2,090,091,000 after acquiring an additional 260,829 shares during the last quarter. BlackRock Inc. grew its position in ABIOMED by 1.5% in the fourth quarter. BlackRock Inc. now owns 3,165,242 shares of the medical equipment provider’s stock valued at $1,028,829,000 after acquiring an additional 47,673 shares during the last quarter. AQR Capital Management LLC grew its position in ABIOMED by 193.5% in the third quarter. AQR Capital Management LLC now owns 1,207,996 shares of the medical equipment provider’s stock valued at $543,297,000 after acquiring an additional 796,482 shares during the last quarter. Finally, Baillie Gifford & Co. grew its position in ABIOMED by 32.8% in the fourth quarter. Baillie Gifford & Co. now owns 1,068,859 shares of the medical equipment provider’s stock valued at $347,422,000 after acquiring an additional 264,252 shares during the last quarter. Hedge funds and other institutional investors own 87.94% of the company’s stock.

NASDAQ:ABMD opened at $270.08 on Monday. The stock has a market cap of $12.26 billion, a PE ratio of 110.24, a PEG ratio of 1.99 and a beta of 0.33. ABIOMED, Inc. has a 1-year low of $267.60 and a 1-year high of $459.75.

ABIOMED (NASDAQ:ABMD) last released its quarterly earnings results on Thursday, January 31st. The medical equipment provider reported $0.97 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.94 by $0.03. The company had revenue of $200.56 million for the quarter, compared to analysts’ expectations of $200.60 million. ABIOMED had a return on equity of 20.31% and a net margin of 30.12%. On average, research analysts anticipate that ABIOMED, Inc. will post 3.83 EPS for the current year.

Several analysts have recently weighed in on the company. Zacks Investment Research cut ABIOMED from a “buy” rating to a “hold” rating in a report on Tuesday, March 19th. BidaskClub cut ABIOMED from a “sell” rating to a “strong sell” rating in a report on Saturday. Finally, BTIG Research restated a “buy” rating and set a $400.00 price target on shares of ABIOMED in a report on Tuesday, January 22nd. They noted that the move was a valuation call. Two analysts have rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the company. The company currently has an average rating of “Hold” and a consensus target price of $422.40.

In related news, Director Martin P. Sutter sold 19,943 shares of ABIOMED stock in a transaction that occurred on Monday, February 4th. The stock was sold at an average price of $350.28, for a total value of $6,985,634.04. Following the transaction, the director now directly owns 212,943 shares of the company’s stock, valued at $74,589,674.04. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Martin P. Sutter sold 5,000 shares of ABIOMED stock in a transaction that occurred on Wednesday, February 13th. The stock was sold at an average price of $360.00, for a total value of $1,800,000.00. Following the completion of the transaction, the director now directly owns 195,491 shares in the company, valued at $70,376,760. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 74,928 shares of company stock worth $26,515,812. 3.50% of the stock is owned by insiders.

ILLEGAL ACTIVITY NOTICE: “ABIOMED, Inc. (ABMD) Holdings Lifted by Valeo Financial Advisors LLC” was first published by Watch List News and is the sole property of of Watch List News. If you are accessing this piece of content on another site, it was copied illegally and reposted in violation of US and international copyright and trademark law. The original version of this piece of content can be viewed at https://www.watchlistnews.com/abiomed-inc-abmd-holdings-lifted-by-valeo-financial-advisors-llc/2963920.html.

About ABIOMED

ABIOMED, Inc engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides continuum of care to heart failure patients. The company offers Impella 2.5 catheter, a percutaneous micro heart pump with integrated motor and sensors for use in interventional cardiology; and Impella CP, a device used by interventional cardiologists to support patients in the cath lab and cardiac surgeons in the heart surgery suite.

Featured Article: What Does a Sell-Side Analyst Rating Mean?

Want to see what other hedge funds are holding ABMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ABIOMED, Inc. (NASDAQ:ABMD).

Institutional Ownership by Quarter for ABIOMED (NASDAQ:ABMD)

Receive News & Ratings for ABIOMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABIOMED and related companies with MarketBeat.com's FREE daily email newsletter.